Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Cyclophosphamide 14Dexamethasone 13Vincristine 11Cytarabine 11Methotrexate 9venetoclax 7Inotuzumab Ozogamicin 7Doxorubicin 7pegaspargase 6merphos 6blinatumomab 6Prednisone 6dexamethasone acetate 5dexamethasone 21-phosphate 5Mercaptopurine 5Calcium Dobesilate 5prednylidene 4deltacortene 4azathiopurine 4auricularum 4Specimen Handling 4Leucovorin 4Asparaginase 4Thioguanine 3Rituximab 3N,N-dicyclohexyl-isoborneol-10-sulfonamide 3Methylprednisolone 3fludarabine 2calaspargase pegol 2asparaginase erwinia chrysanthemi recombinant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma × BEBT-908 × Clear all
NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Ruijin Hospital

Phase 2 Not yet recruiting
23 enrolled
LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡